A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California, San Francisco
San Francisco, California, United States
- Georgetown University
Washington D.C., District of Columbia, United States
- University of Chicago
Chicago, Illinois, United States
- Indiana University
Indianapolis, Indiana, United States
- Johns Hopkins University
Baltimore, Maryland, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- University of Michigan
Ann Arbor, Michigan, United States
- Vanderbilt University
Nashville, Tennessee, United States
- Baylor College of Medicine
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Oct 2015
- Primary completion
- 31 Jan 2021
- Completion
- 31 Jan 2021
- Last update posted
- 16 Mar 2022
- Registered enrollment
- 70
- Registry id
- NCT02384239
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.